The funding included $3m in new equity financing from multiple investors led by SV Tech Ventures and Shangbay Capital, and over $7m in conversion of
previously-issued convertible notes. As part of the financing, ShangBay Capital’s William Dai will join SV Tech’s Peng Cheng on the Emboline board of directors.
Led by Scott Russell, President & CEO, Emboline is advancing a device for total embolic protection during transcatheter aortic valve replacement (TAVR) procedures. The novel Emboliner™ device is intended to protect the cerebral system, while also capturing non-cerebral debris. The company’s technologies are derived from intellectual property invented by Amir Belson, MD, founder of Neoguide Systems, Vascular Pathways, Zipline Medical, Qool Therapeutics, and others.
The capital will be used to fund the SafePass™ Clinical trial for the Emboliner™ Embolic Protection Catheter, the subsequent European CE Mark submission and initial commercial launch.
FinSMEs
19/04/2018